Pharmaceuticals (May 2021)

Genetic and Epigenetic Alterations of <i>CDH1</i> Regulatory Regions in Hereditary and Sporadic Gastric Cancer

  • Gianluca Tedaldi,
  • Chiara Molinari,
  • Celina São José,
  • Rita Barbosa-Matos,
  • Ana André,
  • Rita Danesi,
  • Valentina Arcangeli,
  • Mila Ravegnani,
  • Luca Saragoni,
  • Paolo Morgagni,
  • Francesca Rebuzzi,
  • Matteo Canale,
  • Sara Pignatta,
  • Elisa Ferracci,
  • Giovanni Martinelli,
  • Guglielmina Nadia Ranzani,
  • Carla Oliveira,
  • Daniele Calistri,
  • Paola Ulivi

DOI
https://doi.org/10.3390/ph14050457
Journal volume & issue
Vol. 14, no. 5
p. 457

Abstract

Read online

E-cadherin is a key player in gastric cancer (GC) and germline alterations of CDH1, its encoding gene, are responsible for Hereditary Diffuse Gastric Cancer (HDGC) syndrome. This study aimed at elucidating the role of genetic variants and DNA methylation of CDH1 promoter and enhancers in the regulation of gene expression. For this purpose, we analyzed genetic variants of the CDH1 gene through Next-Generation Sequencing (NGS) in a series of GC cell lines (NCI-N87, KATO-III, SNU-1, SNU-5, GK2, AKG, KKP) and the corresponding CDH1 expression levels. By bisulfite genomic sequencing, we analyzed the methylation status of CDH1 regulatory regions in 8 GC cell lines, in a series of 13 sporadic GC tissues and in a group of 20 HDGC CDH1-negative patients and 6 healthy controls. The NGS analysis on CDH1 coding and regulatory regions detected genetic alterations in 3 out of 5 GC cell lines lacking functional E-cadherin. CDH1 regulatory regions showed different methylation patterns in patients and controls, GC cell lines and GC tissues, expressing different E-cadherin levels. Our results showed that alterations in terms of genetic variants and DNA methylation patterns of both promoter and enhancers are associated with CDH1 expression levels and have a role in its regulation.

Keywords